AstraZeneca makes $15bn manufacturing investment in China

Credit: testing / Shutterstock.com

AstraZeneca is directing $15 billion through 2030 into its medicines manufacturing and R&D operations in China, the firm’s second-largest market.

The biopharma’s investment was announced during the UK Prime Minister’s recent visit to the country, a commitment intended to enhance both life sciences sectors and strengthen the UK-China collaboration in healthcare.

Keir Starmer, UK Prime Minister, said: “AstraZeneca’s expansion and leadership in China will help the British manufacturer continue to grow – supporting thousands of UK jobs.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, reflected that the investment represents “an exciting next chapter for AstraZeneca in China”; one that is set to expand the company’s capabilities “in breakthrough treatments like cell therapy and radioconjugates”, supporting its therapeutic pipelines for cancer, haematological conditions and autoimmune diseases.

AstraZeneca’s investment in China builds on its $1.2 billion acquisition of Gracell Biotechnologies in 2024. The company is set to become the first global biopharmaceutical leader with end-to-end cell therapy capabilities in China.

AstraZeneca also plans to develop its existing manufacturing facilities in Wuxi, Taizhou, Qingdao and Beijing, as well as construct new sites in China.

In addition to expanding its Chinese operations, the company has already committed $50 billion to its US medicines manufacturing and R&D, most recently investing a further $2 billion into its Maryland site. It follows pressure by the US government to onshore manufacturing activities, a shift pursued by other major pharmaceutical companies including Novartis and Eli Lilly.

AstraZeneca’s $15 billion China commitment also supports the firm’s $80 billion revenue target for the end of the decade, a move that will be led in part by recent executive hire Rick Suarez, who will drive the firm’s US efforts.